Bio Medica Laboratories IPO

Listed SME
Min Investment
₹2,78,000
2000 Shares
Min Investment
₹2,78,000 · 2000 Shares
Price Band ₹132–139
Lot Size 1000 shares
Issue Size ₹52 Cr
Listed At ₹111.20 -20%
Subscribed 2.31×
Listed On NSE SME

Bio Medica Laboratories IPO Listing Day Performance

Bio Medica Laboratories listed on NSE SME on 29 May 2026 at ₹111.20, a 20% discount to the issue price of ₹139. A retail investor allotted the minimum application of 2,000 shares (2 lots) lost ₹55,600 at the listing price.

Issue price
₹139
upper band
Listing price
₹111.20
pre-open auction
Listing loss
−20%
−₹27.8 per share
Loss per application
−₹55,600
2,000 shares

GMP vs actual listing

Last GMP before listing₹-6 (-4.3%)
GMP-implied listing₹133
Actual listing₹111.20
Difference−₹21.8 (−16.4%)

Demand going into listing

Subscribed overall2.31×
QIB15.94×
NII1.41×
Retail2.92×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
₹-6
-4.3% ▼ ₹9 since last update
Est. listing ₹133
Upper price ₹139
GMP range ₹-6 – ₹4
18 May · ₹0 28 May · ₹-6
Updated 28 May, 8:35 pm IST Unofficial grey-market data
GMP estimate ₹133
Actual listing ₹111.2
Listed below the GMP estimate by ₹21.8 (-16.4%)
Subscription Status
QIB
15.94x
NII
1.41x
bNII (>10L)
1.02x
sNII (2-10L)
2.19x
Retail
2.92x
Total
2.31x
Updated: May 25, 2026 4:58 pm IST
Analysis Score 37 / 100
Weak Signals
Data: 80%
GMP Score · 44% weight 38
Subscription Score · 38% weight 18
Financial Health · 19% weight 76
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹132–139 per equity share
Face Value₹10 Per Equity Share
Lot Size 1000 shares (Min 2 lots · ₹2,78,000)
Total Issue Size ₹52.43 crore
Fresh Issue₹47.19 crore
Offer For Sale₹5.24 crore
Fresh vs OFS
Fresh 90% · to the company OFS 10% · to selling shareholders
Issue TypeBook build Issue
Lead Manager Narnolia Financial Services Ltd.
Registrar Skyline Financial Services Pvt.Ltd.
Listing atNSE SME
NSE SymbolBMLL
ISININE1BKA01015
Listing Price₹111.20
Listing Gain-20.00%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Total
Each panel has its own scale.
Category Day 1 Day 2 Day 3 Day 5
QIB 15.94x 15.94x 15.94x 15.94x
NII 0.03x 0.38x 0.38x 1.41x
bNII > ₹10L 0.01x 0.35x 0.35x 1.02x
sNII 2-10L 0.06x 0.46x 0.46x 2.19x
Retail 1.09x 1.42x 1.42x 2.92x
Total 0.68x 1.00x 1.00x 2.31x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 2 2,000 ₹2,78,000
Retail Maximum 2 2,000 ₹2,78,000
S-HNI Minimum 3 3,000 ₹4,17,000
S-HNI Maximum 7 7,000 ₹9,73,000
B-HNI Minimum 8 8,000 ₹11,12,000

IPO Reservation

QIB 1% NII 49% Retail 50%
Category Shares Offered Shares %
QIB36,0001.00%
NII (HNI)17,55,00048.98%
bNII > ₹10L11,70,00032.65%
sNII < ₹10L5,85,00016.33%
Retail17,92,00050.01%
Total35,83,000

Financial Analysis

Financial Data

ROE
99.59%
ROCE
48.20%
Debt/Equity
1.02
NAV/Share
₹16.05
Revenue Growth
149.87%
Profit Margin
25.54%

Financial Performance

2025 vs 2024 Revenue +149.9% Profit (PAT) +291.6% Total Assets +100.3%
Metric 2023 2024 2025 Nov 2025
Revenue 16.25 15.34 38.33 28.63
Expense 15.80 11.69 25.18 16.95
Profit (PAT) 0.33 2.50 9.79 8.66
Total Assets 17.57 19.53 39.12 65.17
Values in Crores (₹)

Peer Comparison

Company EPS P/E
Zenotech Laboratories Limited 0.92 -
Shukra Pharmaceuticals Limited 0.22 47.57
Peer median P/E 47.6x across 1 listed peer

Promoters & Holding Pattern

Promoters: Mr. Mukesh Mehta and Mr. Pradeep Mehta

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 91,80,001 99.99%

Strengths & Risks

Strengths
  • Strong institutional (QIB) demand — 15.9x.
  • Revenue grew 150% in the latest reported year.
  • Solid profit margin — 25.5%.
  • Strong return on equity — 100%.
  • Mostly fresh capital — proceeds fund the company's growth, not an exit.
Risks & Concerns
  • Elevated leverage — debt/equity of 1.02.
  • Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Bio Medica Laboratories at a glance

From the company's description: “Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India.”

Bio Medica Laboratories is raising ₹52.43 crore through an IPO on the NSE Emerge (SME). Of that, ₹47.19 crore is a fresh issue — new shares, with the money going to the company — and ₹5.24 crore is an offer for sale by existing shareholders, who keep those proceeds; 90% of the issue therefore reaches the business. Main stated uses of the fresh money: Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (₹24.81 crore) and Repayment of Loan (₹7.25 crore).

Revenue went from ₹16.25 crore in 2023 to ₹38.33 crore in 2025, up 136% over 2 years. Profit after tax went from ₹0.33 crore to ₹9.79 crore, a net margin of 26% in the latest year. The path was not a straight line: revenue dipped in between before recovering.

Debt stands at 1.02 times equity.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Bio Medica Laboratories Ltd., Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore),, Indore, Madhya Pradesh, 452015

Objects of the Issue

Purpose Amount (Cr)
Repayment of Loan 7.25
Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises 24.81
General Corporate Purpose -

Resources & Documents

Bio Medica Laboratories IPO - Quick Take

Bio Medica Laboratories has set a price band of Rs 132–Rs 139 per share for an issue size of Rs 52 crore. The stock listed with a 20.00% discount versus its issue price on May 29, 2026.

The issue is promoted by Mr. Mukesh Mehta and Mr. Pradeep Mehta with Narnolia Financial Services Ltd. acting as lead manager. Net proceeds will primarily be used towards repayment of Loan (Rs 7 crore) and enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (Rs 25 crore).

On fundamentals, the company is posting revenue growth of 149.9%, a profit margin of 25.5%, return on equity of 99.6% in its most recent reported period. Listed peers in this segment include Shukra Pharmaceuticals Limited (P/E 47.57x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read weak — several key indicators are reading below average. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Bio Medica Laboratories IPO: Lead Manager & Registrar Track Record

How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Bio Medica Laboratories itself, so they describe what came before it.

SME IPOs, last 12 months
  • Bio Medica Laboratories listed at −20% on day one; the median of 193 listings was +1.7% (better than 3% of them).
  • Subscribed 2.31x against a median of 4.03x across 192 issues (higher than 39%).
  • Average listing-day move across all 194 SME listings we track: +11.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Narnolia Financial Services Ltd. Lead manager 1 0 MB · 1 SME 100% 1 of 1 +6.9% +6.9%
Skyline Financial Services Pvt.Ltd. Registrar 16 0 MB · 16 SME 75% 12 of 16 Check allotment →
Recent listings managed by Narnolia Financial Services Ltd. (1)
IPOListedListing-day move
Fusion Klassroom 07 Aug 2026 +6.9%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Bio Medica Laboratories listed at Rs 111.20 on 29 May 2026, against an issue price of Rs 139 — a 20% discount.

−20% at the listing price — Rs 27.8 per share, or Rs 55,600 on the minimum retail application of 2,000 shares.

The price band of Bio Medica Laboratories IPO is Rs 132 to Rs 139 per share. Face value is Rs 10 per share.

The total issue size of Bio Medica Laboratories IPO is Rs 52 crore, comprising fresh issue of Rs 47 crore and offer for sale (OFS) of Rs 5 crore.

The lot size of Bio Medica Laboratories IPO is 1,000 shares. The minimum application is 2 lots (2,000 shares), requiring an investment of Rs 2,78,000.

Bio Medica Laboratories IPO opens for subscription on May 21, 2026 and closes on May 25, 2026.

The expected allotment date for Bio Medica Laboratories IPO is May 26, 2026. Refunds for unsuccessful applicants are expected on May 27, 2026.

Bio Medica Laboratories IPO is scheduled to list on May 29, 2026 on NSE. NSE symbol: BMLL, ISIN: INE1BKA01015.

The last GMP (Grey Market Premium) recorded for Bio Medica Laboratories IPO before listing was Rs -6 (-4.3% over issue price). The shares actually listed at Rs 111.2 (-20.00% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Bio Medica Laboratories IPO was subscribed 2.31 times overall by the close of bidding — retail at 2.92x, QIB at 15.94x, NII at 1.41x.

Based on the final retail subscription of 2.92x for Bio Medica Laboratories IPO, the estimated retail allotment probability is approximately 39.0%. This is a moderate probability of allotment.

The registrar for Bio Medica Laboratories IPO is Skyline Financial Services Pvt.Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Bio Medica Laboratories IPO are Narnolia Financial Services Ltd.

The promoter(s) of Bio Medica Laboratories are Mr. Mukesh Mehta and Mr. Pradeep Mehta.

Bio Medica Laboratories IPO GMP — What It Means

Its last GMP before listing was -4.3%. Of the 18 IPOs we have tracked with a final GMP below zero, 2 listed above, 0 flat and 16 below the issue price; Bio Medica Laboratories listed 20% below its issue price.

See the full Bio Medica Laboratories GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Bio Medica Laboratories
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate